New Biomarkers in Pancreatic Cancer Using EXPEL Concept
Recruiting · NCT03791073 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Montpellier
View the official record on ClinicalTrials.gov →What this trial is about
The investigators recently engineered a novel biomarker discovery approach that is non-destructive and fully compatible with OMICS profiling as well as routine clinical procedures (5). The latter approach - termed EXPEL - mines the interstitial tissue fluid that is the richest source of soluble, undiluted and uncontaminated biomarkers. The method notably gives access to proteins, metabolites, RNA, DNA and exosomes, thus enabling holistic biomarker discovery. Owing to its non-destructive nature, EXPEL provides for the first time both clinicians and researchers with the opportunity to analyze identical material. The investigators hypothesize that the conservation liquid used to collect cells and biopsy after endoscopic ultrasound for pancreatic biopsy could contain the tissue secretome and permit a comprehensive OMICS analysis of PDAC (all stages confounded) by using a "modified EXPEL" procedure. These are ideal conditions for EXPEL approach that will additionally to finding novel biomarkers also shed light on complex network of cancer cell-stroma interactions.
Who can take part
Inclusion criteria
- Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy or surgery
- Patient ≥18 years old
- Patient naïve of any treatment of Pancreatic cancer
Exclusion criteria
- Patient who reject the study protocol
Where it is running
1 location listed.
- Uhmontpellier - Montpellier, Montpellier, France